- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01550562
Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation
31. mars 2021 oppdatert av: Boston Scientific Corporation
Precision™ High-Rate Sub-perception Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain
The purpose of this study is to investigate the effects of varying programming parameters in subthreshold spinal cord stimulation therapy for pain relief.
Studieoversikt
Status
Avsluttet
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
1
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
New South Wales
-
Newcastle, New South Wales, Australia, 2292
- Hunter Pain Clinic
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Chronic intractable pain of the trunk and/or limbs
- Documented history of trunk and/or limb pain of at least 180 days
- Average back pain intensity of 5 or greater on a 0-10 numerical rating scale during the 7-day period prior to the Screening Visit
- Pass study site's routine psychological/psychiatric evaluation within 180 days of the Trial Lead Insertion Visit
- If taking any medications for chronic pain, must be on a stable prescription during the 14-day period prior to the Trial Lead Insertion Visit and agree to continue on the same prescription throughout study participation
- Subject is willing and able to comply with all protocol-required procedures and assessments/evaluations
- Subject is able to independently read and complete all questionnaires and/or assessments provided in English
- 18 years of age or older when written informed consent is obtained
- Subject signs a valid, Ethics Committee-approved informed consent form (ICF) provided in English
Exclusion Criteria:
- Unable to operate the PrecisionPlus™ system
- Primary source of pain is cancer-related, pelvic, visceral, angina, or migraine
- Is a high surgical risk
- Is diabetic
- Is immunocompromised
- Currently on any anticoagulant medications that cannot be discontinued during perioperative period
- Untreated major depression or untreated generalized anxiety disorder
- Diagnosed with somatoform disorder, severe personality disorder, borderline personality disorder
- Diagnosed with any major psychiatric disorder not specifically listed in previous two exclusion criterion
- Currently diagnosed with cognitive impairment that would limit subject's ability to discern differences in pain severity, complete a pain diary, perform wound care
- Current abuse of alcohol or illicit drugs
- Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s).
- Subject is participating (or intends to participate) in another investigational drug or device clinical trial that may influence the data that will be collected for this study
- Subject has previously undergone a spinal cord stimulation trial or is already implanted with an active implantable device(s) to treat their pain (IPGs, implantable drug pump, etc) or pacemaker or implantable cardiac defibrillator
- Patient is a woman who is not using adequate contraception, is pregnant or breastfeeding or intends to become pregnant during the course of the study (a urine pregnancy test must be performed within 28 days prior to the Trial Lead Insertion Visit in women of child-bearing potential and the test result document)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Sham Stimulation
Sham subthreshold spinal cord stimulation therapy
|
Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
|
|
Aktiv komparator: Treatment 1
subthreshold spinal cord stimulation therapy
|
Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
|
|
Eksperimentell: Treatment 2
subthreshold spinal cord stimulation therapy
|
Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Relief
Tidsramme: 4,8,and 12 days post temporary lead(s) implantation
|
Mean within-patient difference in average back pain intensity among treatment groups
|
4,8,and 12 days post temporary lead(s) implantation
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Relief Responder Rate
Tidsramme: 4,8,and 12 days post temporary lead(s) implantation
|
Difference in the proportion of subjects with ≥50% reduction in average back pain intensity among treatment groups
|
4,8,and 12 days post temporary lead(s) implantation
|
|
Leg Pain Reduction
Tidsramme: 4,8,and 12 days post temporary lead(s) implantation
|
Mean within-patient difference in average leg pain intensity among treatment groups
|
4,8,and 12 days post temporary lead(s) implantation
|
|
Disability
Tidsramme: 4,8,and 12 days post temporary lead(s) implantation
|
Mean within-patient difference in disability among treatment groups
|
4,8,and 12 days post temporary lead(s) implantation
|
|
Percent Pain Relief
Tidsramme: 4,8,and 12 days post temporary lead(s) implantation
|
Mean within-patient difference in overall percent pain relief among treatment groups
|
4,8,and 12 days post temporary lead(s) implantation
|
|
Quality of Life, as Measured by EQ-5D-5L
Tidsramme: 4,8,and 12 days post temporary lead(s) implantation
|
Mean within-patient difference in quality of life among treatment groups
|
4,8,and 12 days post temporary lead(s) implantation
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Kay Adair, Boston Scientific Corporation
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. februar 2012
Primær fullføring (Faktiske)
1. april 2013
Studiet fullført (Faktiske)
1. april 2013
Datoer for studieregistrering
Først innsendt
15. februar 2012
Først innsendt som oppfylte QC-kriteriene
7. mars 2012
Først lagt ut (Anslag)
12. mars 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
29. april 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
31. mars 2021
Sist bekreftet
1. mars 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- A7002
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .